⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2016OncoTargets and TherapyOpen Access

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

View Full Paper

Ask AI

Bookmark

Share

Authors

KRKimberly RedicUniversity of Michigan SHShannon HoughMcKesson (United States)EPE. Shane Price

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Redic et al. (2016) studied this question.

synapsesocial.com/papers/6a729ed9f44fa9f079e0090c https://doi.org/10.2147/ott.s87962

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

1Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma2005 · 599 citations